Loading organizations...
§ Private Profile · San Francisco, CA, USA
Swing Therapeutics is a technology company.
Swing Therapeutics develops digital therapies that help people with chronic illness live their best lives. Stanza, an FDA-cleared digital therapy for treatment of fibromyalgia symptoms, is now available by prescription.
Swing Therapeutics has raised $19.0M across 2 funding rounds.
Swing Therapeutics has raised $19.0M in total across 2 funding rounds.
Swing Therapeutics has raised $19.0M in total across 2 funding rounds.
Swing Therapeutics's investors include Jazz Venture Partners, Bling Capital, General Atlantic, Khosla Ventures, Polaris Partners, Sovereign Internet and Identity, Jeff Hammerbacher, Alumni Ventures, AME Cloud Ventures, Asahi Kasei Ventures, Gaingels, Laura Rippy.
Swing Therapeutics has raised $19.0M across 2 funding rounds. Most recently, it raised $10.0M Series A in June 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2022 | $10M Series A | JAZZ Venture Partners | Bling Capital, General Atlantic, Khosla Ventures, Polaris Partners, Sovereign Internet And Identity, Jeff Hammerbacher, Alumni Ventures, AME Cloud Ventures, Asahi Kasei Ventures, Gaingels, Laura Rippy, Kicker Ventures, Mana Ventures, Chelsea Clinton | Announced |
| Aug 1, 2021 | $9M Seed | JAZZ Venture Partners | Bling Capital, General Atlantic, Khosla Ventures, Polaris Partners, Sovereign Internet And Identity, Jeff Hammerbacher | Announced |
Swing Therapeutics is a digital therapeutics company focused on developing evidence-backed, software-based treatments for chronic and autoimmune conditions, particularly fibromyalgia and chronic overlapping pain conditions (COPCs). Their flagship product is a smartphone-based digital therapeutic program delivering Acceptance and Commitment Therapy (ACT), a form of cognitive behavioral therapy (CBT), adapted from a clinically validated program licensed from the University of Manitoba. This product aims to improve symptom management and function for patients underserved by traditional treatments. Swing Therapeutics serves patients with fibromyalgia and related chronic pain conditions, addressing the significant unmet need for effective, accessible therapies. The company has demonstrated growth momentum through FDA Breakthrough Device Designation and ongoing clinical trials, positioning it as a promising innovator in digital health[1][2][5].
Founded in 2019 by Mike Rosenbluth, Ph.D., Swing Therapeutics emerged from the recognition that many chronic pain and autoimmune conditions lack effective treatment options and that digital interventions could fill this gap. The company licensed a foundational ACT program from the University of Manitoba and adapted it for modern smartphone use, enhancing accessibility and engagement. Early traction included securing $9 million in seed funding led by JAZZ Venture Partners and receiving FDA Breakthrough Device Designation for their fibromyalgia digital therapeutic. These milestones validated their approach and supported the launch of pivotal clinical trials to demonstrate safety and efficacy[1][2].
Swing Therapeutics rides the growing trend of digital therapeutics as a transformative approach to managing chronic diseases, especially where pharmacological options are limited or insufficient. The timing is critical given increasing healthcare digitization, patient demand for accessible care, and regulatory openness to software-based treatments. Market forces such as rising chronic pain prevalence, healthcare cost pressures, and advances in behavioral therapy digitization favor Swing’s model. By pioneering FDA-recognized digital therapies, Swing influences the broader ecosystem by validating digital therapeutics as credible, scalable alternatives or complements to traditional care[1][2].
Looking ahead, Swing Therapeutics is poised to expand its clinical trial portfolio and move toward broader regulatory approvals and market adoption. Trends shaping its journey include increasing acceptance of digital health solutions, advances in personalized behavioral therapies, and integration with virtual care platforms. As the company scales, it may broaden its therapeutic focus beyond fibromyalgia to other chronic and autoimmune conditions. Swing’s influence is likely to grow as it helps set standards for digital therapeutic efficacy and regulatory pathways, potentially reshaping chronic disease management paradigms. Their mission to improve access to effective, patient-centered digital treatments remains central to their evolving impact[1][2][4].